180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 15:59:54 2024-06-07 EDT			5-day change	1st Jan Change
1.62 ^USD	-6.90%		0.00%	-60.06%

05-15	180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	180 Life Sciences Corp. Announces Management Changes	CI

Marlene Krauss Assume the Role of CEO of the Combined Company of KBL Merger Corp. IV's Wholly Owned Subsidiary and Cannbiorx Life Sciences Corp

July 26, 2019 at 09:00 am

KBL Merger Corp. IV announced that it has executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with CannBioRx Life Sciences Corp. Marlene Krauss, CEO of KBLM, who will also assume the role of CEO of the combined company.

Latest news about 180 Life Sciences Corp.

180 Life Sciences Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
180 Life Sciences Corp. Announces Management Changes	05-09	CI
180 Life Sciences Corp. Announces Chief Executive Officer Changes	05-09	CI
180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
180 Life Sciences Corp. Announces Board Changes	03-11	CI
180 Life Sciences Corp. Appoints Blair Jordan as A Member of the Board of Directors	02-29	CI
180 Life Sciences to Conduct 1-For-19 Reverse Stock Split	02-26	MT
180 Life Sciences Corp. announced a financing transaction	02-20	CI
180 Life Sciences Corp. Announces Board Resignations	12-21	CI
180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors	12-20	CI
180 Life Sciences Hires Financial Adviser to Help Explore Strategic Alternatives	12-04	CI
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives	12-03	CI
180 Life Sciences Announces Review of Strategic Alternatives	11-28	CI
Certain Warrants of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	11-12	CI
Certain Stock Options of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	11-12	CI
Certain Common Stock of 180 Life Sciences Corp. are subject to a Lock-Up Agreement Ending on 13-NOV-2023.	11-12	CI
180 Life Sciences Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency	23-10-18	CI
180 Life Sciences Corp. and Oxford University Innovation Limited Enter into a Termination Letter, Formally Terminate the License	23-09-28	CI
180 Life Sciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Top Premarket Gainers	23-08-09	MT
180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake	23-08-07	CI
180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment	23-08-03	CI
180 Life Sciences Corp. Announces the Filing of A Provisional Patent Describing the Combination of CBD with GLP-1 Agonists to Suppress Appetite	23-07-31	CI
180 Life Sciences Corp.(NasdaqCM:ATNF) dropped from Russell 3000E Growth Index	23-06-23	CI

Chart 180 Life Sciences Corp.

Duration

Period

More charts

Company Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
180 LIFE SCIENCES CORP.	-60.06%	1.38M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B

Bio Therapeutic Drugs

180 Life Sciences Corp.

Equities

KBLM

US68236V3024

Biotechnology & Medical Research

Marlene Krauss Assume the Role of CEO of the Combined Company of KBL Merger Corp. IV's Wholly Owned Subsidiary and Cannbiorx Life Sciences Corp

Latest news about 180 Life Sciences Corp.

Chart 180 Life Sciences Corp.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs